These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 1299176

  • 1. Antilymphocyte globulin with a small dose of cyclosporine A and prednisone as the induction of immunosuppression in renal allograft recipients.
    Boratyńska M, Szepietowski T, Szewczyk Z, Szydłowski Z.
    Arch Immunol Ther Exp (Warsz); 1992; 40(2):163-8. PubMed ID: 1299176
    [Abstract] [Full Text] [Related]

  • 2. 20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients.
    Cantarovich M, Durrbach A, Hiesse C, Ladouceur M, Benoit G, Charpentier B.
    Transplantation; 2008 Dec 27; 86(12):1732-7. PubMed ID: 19104413
    [Abstract] [Full Text] [Related]

  • 3. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
    Grino JM, Castelao AM, Serón D, Gonzalez C, Galceran JM, Gil-Vernet S, Andrés E, Mestre M, Torras J, Alsina J.
    Am J Kidney Dis; 1992 Dec 27; 20(6):603-10. PubMed ID: 1462990
    [Abstract] [Full Text] [Related]

  • 4. Beneficial effect of concomitant induction with antilymphoblast globulin, cyclosporine, and steroids on long-term renal allograft outcome.
    Koga A, Moreso FJ, Seron D, Gil-Vernet S, Cruzado JM, Castelao AM, Grinyó JM.
    Transplant Proc; 2004 Jun 27; 36(5):1305-7. PubMed ID: 15251318
    [Abstract] [Full Text] [Related]

  • 5. Induction therapy with cyclosporine without cytolytic agents results in a low incidence of acute rejection without significant renal impairment in heart transplant patients.
    Jazzar A, Fagiuoli S, Sisson S, Zuhdi N, Cooper DK.
    Clin Transplant; 1995 Aug 27; 9(4):334-9. PubMed ID: 7579743
    [Abstract] [Full Text] [Related]

  • 6. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients.
    Grimbert P, Baron C, Fruchaud G, Hemery F, Desvaux D, Buisson C, Chopin D, Dahmane D, Remy P, Pastural M, Abbou C, Weil B, Lang P.
    Transpl Int; 2002 Nov 27; 15(11):550-5. PubMed ID: 12461659
    [Abstract] [Full Text] [Related]

  • 7. Individualization of immediate posttransplant immunosuppression. The value of antilymphocyte globulin in patients with delayed graft function.
    Matas AJ, Tellis VA, Quinn TA, Glicklich D, Soberman R, Veith FJ.
    Transplantation; 1988 Feb 27; 45(2):406-9. PubMed ID: 3278434
    [Abstract] [Full Text] [Related]

  • 8. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
    Cantarovich M, Latter DA, Loertscher R.
    Clin Transplant; 1997 Aug 27; 11(4):316-21. PubMed ID: 9267721
    [Abstract] [Full Text] [Related]

  • 9. Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers.
    Shabtai M, Ben-Haim M, Zemer D, Malinger-Saavedra P, Rosin D, Kuriansky J, Lustig S, Shabtai EL, Shapira Z, Ayalon A.
    Isr Med Assoc J; 2002 Nov 27; 4(11 Suppl):935-9. PubMed ID: 12455184
    [Abstract] [Full Text] [Related]

  • 10. Effect of early cyclosporine levels on kidney allograft rejection.
    Johnson EM, Canafax DM, Gillingham KJ, Humar A, Pandian K, Kerr SR, Najarian JS, Matas AJ.
    Clin Transplant; 1997 Dec 27; 11(6):552-7. PubMed ID: 9408683
    [Abstract] [Full Text] [Related]

  • 11. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients.
    Gruber SA, Gillingham K, Sothern RB, Stephanian E, Matas AJ, Dunn DL.
    Clin Transplant; 1994 Aug 27; 8(4):388-95. PubMed ID: 7949545
    [Abstract] [Full Text] [Related]

  • 12. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
    Prieto M, Lake KD, Pritzker MR, Jorgensen CR, Arom KV, Love KR, Emery RW.
    J Heart Lung Transplant; 1991 Aug 27; 10(6):901-11. PubMed ID: 1661608
    [Abstract] [Full Text] [Related]

  • 13. Cyclosporine-based immunosuppressive strategies for kidney recipients: interim analysis of German data from the Multinational Observational Study (MOST).
    Kliem V, Fritsche L, Haller H, Suwelack B, Abendroth D, Fornara P, Pietruck F, Frei U, Donauer J, Lison AE, Michel U, Ulbricht B, International MOST Study Group.
    Transplant Proc; 2005 Apr 27; 37(3):1597-600. PubMed ID: 15866683
    [Abstract] [Full Text] [Related]

  • 14. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.
    Boratyńska M, Banasik M, Patrzalek D, Szyber P, Klinger M.
    Transplant Proc; 2005 Mar 27; 37(2):839-42. PubMed ID: 15848550
    [Abstract] [Full Text] [Related]

  • 15. Renal transplantation at the University of Minnesota during the 1980s.
    Fryd DS, Migliori R, Simmons RL, Chavers B, Dunn D, Payne W, Canafax DM, Sutherland DE, So SS, Mauer SM.
    Clin Transpl; 1987 Mar 27; ():167-81. PubMed ID: 3154396
    [Abstract] [Full Text] [Related]

  • 16. Bone marrow function during quadruple immunosuppressive therapy after renal transplantation.
    Heaf J.
    Clin Nephrol; 1993 Dec 27; 40(6):332-8. PubMed ID: 8299241
    [Abstract] [Full Text] [Related]

  • 17. Randomized study comparing cyclosporine with azathioprine one year after renal transplantation-15-year outcome data.
    Joss N, Rodger RS, McMillan MA, Junor BJ.
    Transplantation; 2007 Mar 15; 83(5):582-7. PubMed ID: 17353778
    [Abstract] [Full Text] [Related]

  • 18. A prospective randomized controlled trial of initial immunosuppression with ALG versus OKT3 in recipients of cardiac allografts.
    Menkis AH, Powell AM, Novick RJ, McKenzie FN, Kostuk WJ, Pflugfelder PW, Brown JE, Rochon J, Chow LH, Stiller C.
    J Heart Lung Transplant; 1992 Mar 15; 11(3 Pt 1):569-76. PubMed ID: 1610866
    [Abstract] [Full Text] [Related]

  • 19. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G, Walsh G, Deshpande P, Koffman G.
    Nephrol Dial Transplant; 2002 Jul 15; 17(7):1304-9. PubMed ID: 12105256
    [Abstract] [Full Text] [Related]

  • 20. Antilymphocyte globulins versus OKT3 as prophylactic treatment in highly sensitized renal transplant recipients.
    Vela C, Cristol JP, Chong G, Okamba A, Lorho R, Mion C, Mourad G.
    Transpl Int; 1994 Jul 15; 7 Suppl 1():S259-62. PubMed ID: 11271219
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.